It’s only fair to share… PF-06651600 CAS 1792180-81-4 C₁₅H₁₉N₅O, 285.34, UNII-2OYE00PC25 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one 1-[(2S,5R)-2-Methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one malonate PF-06651600 malonate CAS: 2140301-97-7 (malonate) Chemical Formula: C18H23N5O5 Molecular Weight: 389.412 PHASE 2 alopecia areata, rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. PF-06651600 is a potent and selective JAK3 inhibitor. PF-06651600 is a potent and low clearance compound with demonstrated in vivo efficacy. The …
Category «Phase 2»
Fluazolepali, 氟唑帕利 , Fluzoparib
It’s only fair to share… Fluazolepali CAS 2170504-09-1 Fluzoparib; SHR-3162, (HS10160) HS 10160 SHR 3162 An orally available inhibitor of poly(ADP-ribose) polymerase 1 and 2 (PARP-1/2) for treatment of solid tumors (Jiangsu Hengrui Medicine Co. Ltd., Lianyungang, China) Fluazolepali, developed by Hengrui and Howson, is intended for the treatment of recurrent ovarian cancer, triple-negative breast …
Tanzisertib
It’s only fair to share… Tanzisertib CAS 899805-25-5 trans-4-((9-((3S)-Tetrahydrofuran-3-yl)-8-((2,4,6-trifluorophenyl)amino)-9H-purin-2-yl)amino)cyclohexanol 4-[[9-[(3S)-oxolan-3-yl]-8-(2,4,6-trifluoroanilino)purin-2-yl]amino]cyclohexan-1-ol C21-H23-F3-N6-O2, 448.4467 9557 Cyclohexanol, 4-[[9-[(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-, trans- CC 930 CC-930 Tanzisertib UNII-M5O06306UO A c-Jun amino-terminal kinase inhibitor.UNII, M5O06306UO Treatment of Idiopathic Pulmonary Fibrosis (IPF) Originator Celgene Corporation Class Antifibrotics; Small molecules Mechanism of ActionJ NK mitogen-activated protein kinase inhibitors Orphan Drug Status Yes – Idiopathic pulmonary fibrosis Discontinued Discoid lupus erythematosus; …
Ceralasertib, AZD 6738
It’s only fair to share… AZD-6738, Ceralasertib Molecular Formula C20H24N6O2S Average mass 412.509 Da CAS 1352226-88-0 [RN] 1H-Pyrrolo[2,3-c]pyridine, 4-[4-[(3R)-3-methyl-4-morpholinyl]-6-[1-(S-methylsulfonimidoyl)cyclopropyl]-2-pyrimidinyl]- 4-{4-[(3R)-3-Methyl-4-morpholinyl]-6-[1-(S-methylsulfonimidoyl)cyclopropyl]-2-pyrimidinyl}-1H-pyrrolo[2,3-c]pyridine 1H-Pyrrolo(2,3-b)pyridine, 4-(4-(1-((S(R))-S-methylsulfonimidoyl)cyclopropyl)-6-((3R)-3-methyl-4-morpholinyl)-2-pyrimidinyl)- imino-methyl-[1-[6-[(3R)-3-methylmorpholin-4-yl]-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl]cyclopropyl]-oxo-λ6-sulfane 85RE35306Z AZD-6738 UNII:85RE35306Z CAS : 1352226-88-0 (free base) 1352280-98-8 (formic acid) 1352226-97-1 (racemic) 4-[4-[1-[[S(R)]-S-Methylsulfonimidoyl]cyclopropyl]-6-[(3R)-3-methyl-4-morpholinyl]-2-pyrimidinyl]-1H-pyrrolo[2,3-b]pyridine AZD 6738 Ceralasertib Originator AstraZeneca; University of Pennsylvania Class Antineoplastics; Morpholines; Pyrimidines; Small molecules Mechanism of Action ATR protein inhibitors Phase II Breast cancer; Gastric cancer; Non-small cell …
HEC-68498
It’s only fair to share… HEC-68498, CT-365 CAS 1621718-37-3 C20 H13 F2 N5 O3 S 441.41 Benzenesulfonamide, N-[5-(3-cyanopyrazolo[1,5-a]pyridin-5-yl)-2-methoxy-3-pyridinyl]-2,4-difluoro- N-[5-(3-Cyanopyrazolo[1,5-a]pyridin-5-yl)-2-methoxy-3-pyridinyl]-2,4-difluorobenzenesulfonamide HEC Pharm , Calitor Sciences Llc; Sunshine Lake Pharma Co Ltd PHASE 1, idiopathic pulmonary fibrosis and solid tumors Phosphoinositide 3-kinase inhibitor; mTOR inhibitor Originator HEC Pharm Developer HEC Pharm; Sunshine Lake Pharma Class Anti-inflammatories; Antifibrotics; Isoenzymes Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors …
SEVITERONEL, севитеронел , سيفيتيرونيل , 赛维罗奈 ,
It’s only fair to share… SEVITERONEL CAS Registry Number 1610537-15-9 Molecular formulaC18 H17 F4 N3 O3, MW 399.34 1H-1,2,3-Triazole-5-methanol, α-[6,7-bis(difluoromethoxy)-2-naphthalenyl]-α-(1-methylethyl)-, (αS)- (αS)-α-[6,7-Bis(difluoromethoxy)-2-naphthalenyl]-α-(1-methylethyl)-1H-1,2,3-triazole-5-methanol 8S5OIN36X4 севитеронел [Russian] [INN] سيفيتيرونيل [Arabic] [INN] 赛维罗奈 [Chinese] [INN] Mechanism of ActionAndrogen receptor antagonists; Estrogen receptor antagonists; Steroid 17-alpha-hydroxylase inhibitors; Steroid 17-alpha-hydroxylase modulators WHO ATC codeL01 (Antineoplastic Agents)L01X-X (Other antineoplastic agents) EPhMRA codeL1 (Antineoplastics)L1X9 (All other antineoplastics) 1H-1,2,3-Triazole-5-methanol, alpha-(6,7-bis(difluoromethoxy)-2-naphthalenyl)-alpha-(1-methylethyl)-, (alphaS)- …
CT-1812
It’s only fair to share… CT-1812 Elayta Condition(s): Alzheimer’s Disease U.S. FDA Status: Alzheimer’s Disease (Phase 2) Company: Cognition Therapeutics Inc. CAS: 1802632-22-9 Chemical Formula: C24H33NO4S Molecular Weight: 431.591 2-(tert-butoxy)-4-(3-methyl-3-(5-(methylsulfonyl)isoindolin-2-yl)butyl)phenol Phenol, 4-[3-[1,3-dihydro-5-(methylsulfonyl)-2H-isoindol-2-yl]-3-methylbutyl]-2-(1,1-dimethylethoxy)- Originator Cognition Therapeutics Class Antidementias; Neuroprotectants; Nootropics; Small molecules Mechanism of Action Sigma-2 receptor antagonists Phase II Alzheimer’s disease Phase I Cognition disorders 21 Feb 2019 Cognition Therapeutics receives patent for …
Aclimostat
It’s only fair to share… Aclimostat CAS: 2082752-83-6 Chemical Formula: C26H42N2O6 Molecular Weight: 478.63 Elemental Analysis: C, 65.25; H, 8.85; N, 5.85; O, 20.06 ZGN-1061; ZGN1061; ZGN 1061; Aclimostat, UNII-X150A3JK8R X150A3JK8R (3R,4S,5S,6R)-5-Methoxy-4-[(2R,3R)-2-methyl-3-(3- methylbut-2-en-1-yl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl 3-[2-(morpholin-4-yl)ethyl]azetidine-1-carboxylate 1-Azetidinecarboxylic acid, 3-[2-(4-morpholinyl)ethyl]-, (3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-2-buten-1-yl)-2-oxiranyl]-1-oxaspiro[2.5]oct-6-yl ester 3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1- oxaspiro[2.5]octan-6-yl 3-(2-morpholinoethyl)azetidine-1-carboxylate ZAFGEN, PHASE 2, DIABETES Aclimostat, also known as ZGN-1061, is an anti-diabetic, anti-obesity …
Cavosonstat (N-91115)
It’s only fair to share… Cavosonstat (N-91115) CAS 1371587-51-7 C16H10ClNO3, 299.71 g/mol UNII-O2Z8Q22ZE4, O2Z8Q22ZE4, NCT02589236; N91115-2CF-05; SNO-6 3-chloro-4-(6-hydroxyquinolin-2-yl)benzoic acid Treatment of Chronic Obstructive Pulmonary Diseases (COPD), AND Cystic fibrosis, Nivalis Therapeutics, phase 2 The product was originated at Nivalis Therapeutics, which was acquired by Alpine Immune Sciences in 2017. In 2018, Alpine announced the sale and transfer of global rights to …
Deutivacaftor
It’s only fair to share… Deutivacaftor RN: 1413431-07-8 UNII: SHA6U5FJZL, N-[2-tert-butyl-4-[1,1,1,3,3,3-hexadeuterio-2-(trideuteriomethyl)propan-2-yl]-5-hydroxyphenyl]-4-oxo-1H-quinoline-3-carboxamide Molecular Formula, C24-H28-N2-O3, Molecular Weight, 401.552 Synonyms CTP-656 D9-ivacaftor Deutivacaftor Ivacaftor D9 UNII-SHA6U5FJZL VX-561 WHO 10704 Treatment of Cystic Fibrosis Originator Concert Pharmaceuticals Class Amides; Aminophenols; Antifibrotics; Organic deuterium compounds; Quinolones; Small molecules Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants Orphan Drug Status Yes – Cystic fibrosis Phase II Cystic …